Pharma Industry News
Novo Nordisk: Financial Statement for the Period 1 January 2007 to 30 June 2007
Novo
Nordisk increased first half-year operating profit by 14% and
raises the expectation for 2007 operating
profit growth to around 10%
- Novo Nordisk increased sales by 14% in local currencies and - due to a significant negative currency development - by 9% in Danish kroner.
- Sales of modern insulins increased by 37% (31% in Danish kroner).
- Sales of NovoSeven® increased by 11% (5% in Danish kroner).
- Sales of Norditropin® increased by 13% (7% in Danish kroner).
- Sales in North America increased by 25% (16% in Danish kroner).
- Gross margin increased to 77.0% in the first six months of 2007 up from 75.0% in the same period last year, primarily reflecting continued productivity improvements.
- Operating profit increased by 14% to DKK 5,134 million. Adjusted for the impact from currencies underlying operating profit increased by around 25%.
- Net profit increased by 81% to DKK 5,361 million, primarily reflecting the divestment of Dako's business activities. Earnings per share (diluted) increased by 84% to DKK 16.76.
- The full-year expectation for operating profit growth is now around 10%, primarily reflecting a sustainable improvement in gross margin. Measured in local currencies the expectation for full-year operating profit growth is now increased to around 20%.
- Novo Nordisk has announced very positive results from the first phase 3 study with liraglutide, a human GLP-1 analogue, showing that liraglutide is statistically superior to insulin glargine in terms of blood glucose control and weight loss.
COPENHAGEN, Aug. 3, 2007-Lars Rebien
Sørensen, president and CEO, said: "The business continues
to perform very well with robust sales growth and a sustained
improvement in our gross margin. We are also very pleased with the
first phase 3 results on liraglutide which are expected to be
supported by results from additional phase 3 studies during the
following months."
Contacts for further
information:
|
Media:
|
Investors:
|
|
|
|
|
Outside North
America:
|
Outside North
America:
|
|
Mike Rulis
|
Mads Veggerby Lausten
|
|
Tel (direct): (+45) 4442 3573
|
Tel (direct): (+45) 4443 7919
|
|
E-mail:
mike@novonordisk.com
|
E-mail: mlau@novonordisk.com
|
|
|
|
|
|
Hans Rommer
|
|
|
Tel (direct): (+45) 4442 4765
|
|
|
E-mail: hrmm@novonordisk.com
|
|
|
|
|
In North America:
|
In North America:
|
|
Lori Moore
|
Christian Qvist Frandsen
|
|
Tel (direct): (+1) 609 919 7991
E-mail: lrmo@novonordisk.com
|
Tel (direct): (+1) 609 919 7937
E-mail: cqfr@novonordisk.com
|
Pharma Industry News Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
